William Richard White - Jul 6, 2021 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role: Chief Financial Officer
Signature: /s/ Jonathan Young, Attorney-in-fact
Stock symbol: AKRO
Transactions as of: Jul 6, 2021
Transactions value $: -$113,822
Form type: 4
Date filed: 7/8/2021, 07:19 PM
Next filing: Aug 4, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKRO	Common Stock	Options Exercise	$45.6K	+6.5K	+198.35%	$7.01^*	9.78K	Jul 6, 2021	Direct
transaction	AKRO	Common Stock	Sale	-$159K	-6.5K	-66.48%	$24.52	3.28K	Jul 6, 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKRO	Stock Option (Right to Buy)	Options Exercise	$0	-6.5K	-1.81%	$0.00	353K	Jul 6, 2021	Common Stock	6.5K	$7.01	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares sold pursuant to a Rule 10b5-1 trading plan dated June 2, 2021 previously adopted by the Reporting Person.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $24.12 to $24.80, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3	25% of this option vested on April 1, 2020, and the remaining 75% of this option shall vest in 36 equal monthly installments thereafter.